Palliative care in lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition)

Chest

Volumn 132, Issue 3 SUPPL., 2007, Pages 368S-403S

  Kvale, Paul A ^a   Selecky, Paul A ^b   Prakash, Udaya B S ^c  

^a HENRY FORD HEALTH SYSTEM   (United States)

^b HOAG MEMORIAL HOSPITAL PRESBYTERIAN   (United States)

^c MAYO CLINIC   (United States)

Author keywords

Bone metastases; Brain metastases; Cough; Dyspnea; Electrocautery; Hemoptysis; Interventional bronchoscopy; Laser; Pain management; Pleural effusions; Spinal cord metastases; Superior vena cava syndrome; Tracheoesophageal fistula

Indexed keywords

ANTICONVULSIVE AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; BENZONATATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BISPHOSPHONIC ACID DERIVATIVE; BRONCHODILATING AGENT; BUSPIRONE; CALCITONIN; CARBAMAZEPINE; CLONAZEPAM; CODEINE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; FENTANYL; FUROSEMIDE; HYDROCODONE; HYDROXYZINE; KETAMINE; MORPHINE; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OXYMORPHONE; PARACETAMOL; PETHIDINE; PHENOTHIAZINE; PHENYTOIN; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

AGITATION; BONE METASTASIS; BRAIN EDEMA; BRAIN METASTASIS; CANCER PAIN; CANCER PALLIATIVE THERAPY; COMORBIDITY; COUGHING; DYSPHORIA; DYSPNEA; HEMOPTYSIS; HUMAN; LIVER METASTASIS; LUNG CANCER; MEDLINE; METASTASIS; NEUROPATHIC PAIN; PLEURA EFFUSION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SEIZURE; SIDE EFFECT; SPINAL CORD METASTASIS; SUPERIOR CAVA VEIN SYNDROME; THORAX PAIN; TRACHEOESOPHAGEAL FISTULA; WHEEZING; ARTICLE; EVIDENCE BASED MEDICINE; LUNG TUMOR; METHODOLOGY; PALLIATIVE THERAPY;

EVIDENCE-BASED MEDICINE; HUMANS; LUNG NEOPLASMS; PALLIATIVE CARE;

EID: 34848859841     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.07-1391     Document Type: Article

References (358)

1. Brown J, Thorpe H, Napp V, et al. Assessment of quality of life in the supportive care setting of the big lung trial in non-small-cell lung cancer. J Clin Oncol 2005; 23:7417-7427
2. Chute CG, Greenberg ER, Baron J, et al. Presenting conditions of 1539 population-based lung cancer patients by cell type and stage in New Hampshire and Vermont. Cancer 1985; 56:2107-2111
3. Colice GL. Detecting lung cancer as a cause of hemoptysis in patients with a normal chest radiograph: bronchoscopy vs CT. Chest 1997; 111:877-884
4. Grippi MA. Clinical aspects of lung cancer. Semin Roentgenol 1990; 25:12-24
5. Hamilton W, Peters TJ, Round A, et al. What are the clinical features of lung cancer before the diagnosis is made? A population based case-control study. Thorax 2005; 60:1059-1065
6. Hyde L, Hyde CI. Clinical manifestations of lung cancer. Chest 1974; 65:299-306
7. Kvale PA. Chronic cough due to lung tumors: ACCP evidence-based clinical practice guidelines. Chest 2006; 129:147S-153S
8. Antunes G, Neville E, Duffy J, et al. BTS guidelines for the management of malignant pleural effusions. Thorax 2003; 58(suppl):ii29-ii38
9. Bennett R, Maskell N. Management of malignant pleural effusions. Curr Opin Pulm Med 2005; 11:296-300
10. Bonnefoi H, Smith IE. How should cancer presenting as a malignant pleural effusion be managed? Br J Cancer 1996; 74:832-835
11. Gauwitz M, Ellerbroek N, Komaki R, et al. High dose endobronchial irradiation in recurrent bronchogenic carcinoma. Int J Radiat Oncol Biol Phys 1992; 23:397-400
12. Hernandez P, Gursahaney A, Roman T, et al. High dose rate brachytherapy for the local control of endobronchial carcinoma following external irradiation. Thorax 1996; 51:354-358
13. Sirbu H, Busch T, Aleksic I, et al. Bronchopleural fistula in the surgery of non-small cell lung cancer: incidence, risk factors, and management. Ann Thorac Cardiovasc Surg 2001; 7:330-336
14. Sonobe M, Nakagawa M, Ichinose M, et al. Analysis of risk factors in bronchopleural fistula after pulmonary resection for primary lung cancer. Eur J Cardiothorac Surg 2000; 18:519-523
15. Speiser BL, Spratling L. Radiation bronchitis and stenosis secondary to high dose rate endobronchial irradiation. Int J Radiat Oncol Biol Phys 1993; 25:589-597
16. Suzuki M, Otsuji M, Baba M, et al. Bronchopleural fistula after lung cancer surgery: multivariate analysis of risk factors. J Cardiovasc Surg (Torino) 2002; 43:263-267
17. Urban T, Lebeau B, Chastang C, et al. Superior vena cava syndrome in small-cell lung cancer. Arch Intern Med 1993; 153:384-387
18. Wurschmidt F, Bunemann H, Heilmann HP. Small cell lung cancer with and without superior vena cava syndrome: a multivariate analysis of prognostic factors in 408 cases. Int J Radiat Oncol Biol Phys 1995; 33:77-82
19. Apolinario RM, van der Valk P, de Jong JS, et al. Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer. J Clin Oncol 1997; 15:2456-2466
20. Byhardt RW, Martin L, Pajak TF, et al. The influence of field size and other treatment factors on pulmonary toxicity following hyperfractionated irradiation for inoperable non-small cell lung cancer (NSCLC): analysis of a Radiation Therapy Oncology Group (RTOG) protocol. Int J Radiat Oncol Biol Phys 1993; 27:537-544
21. Grills IS, Yan D, Martinez AA, et al. Potential for reduced toxicity and dose escalation in the treatment of inoperable non-small-cell lung cancer: a comparison of intensity-modulated radiation therapy (IMRT), 3D conformai radiation, and elective nodal irradiation. Int J Radiat Oncol Biol Phys 2003; 57:875-890
22. Hernando ML, Marks LB, Bentel GC, et al. Radiation-induced pulmonary toxicity: a dose-volume histogram analysis in 201 patients with lung cancer. Int J Radiat Oncol Biol Phys 2001; 51:650-659
23. Jeremic B, Shibamoto Y, Milicic B, et al. Impact of treatment interruptions due to toxicity on outcome of patients with early stage (I/II) non-small-cell lung cancer (NSCLC) treated with hyperfractionated radiation therapy alone. Lung Cancer 2003; 40:317-323
24. Kong FM, Ten Haken R, Eisbruch A, et al. Non-small cell lung cancer therapy-related pulmonary toxicity: an update on radiation pneumonitis and fibrosis. Semin Oncol 2005; 32:S42-S54
25. Miller KL, Shafman TD, Anscher MS, et al. Bronchial stenosis: an underreported complication of high-dose external beam radiotherapy for lung cancer? Int J Radiat Oncol Biol Phys 2005; 61:64-69
26. Sunyach MP, Falchero L, Pommier P, et al. Prospective evaluation of early lung toxicity following three-dimensional conformai radiation therapy in non-small-cell lung cancer: preliminary results. Int J Radiat Oncol Biol Phys 2000; 48:459-463
27. Van Houtte P, Danhier S, Mornex F. Toxicity of combined radiation and chemotherapy in non-small cell lung cancer. Lung Cancer 1994; 10(suppl):S271-S280
28. Cooley ME. Symptoms in adults with lung cancer: a systematic research review. J Pain Symptom Manage 2000; 19:137-153
29. Gordon DB, Dahl JL, Miaskowski C, et al. American Pain Society recommendations for improving the quality of acute and cancer pain management: American Pain Society Quality of Care Task Force. Arch Intern Med 2005; 165:1574-1580
30. Jacox A, Carr DB, Payne R. Management of cancer pain. Rockville, MD: Agency for Health Care Policy and Research, U.S. Department of Health and Human Services, Public Health Service, 1994
31. Goudas L, Carr DB, Bloch R. Management of cancer pain, Rockville, MD: Agency for Healthcare Research and Quality, 2001
32. Miaskowski C, Cleary J, Burney R, et al. Guideline for the management of cancer pain in adults and children. Glenview, IL: American Pain Society, 2005
33. Cepeda MS, Africano JM, Polo R, et al. What decline in pain intensity is meaningful to patients with acute pain? Pain 2003; 105:151-157
34. Farrar JT, Berlin JA, Strom BL. Clinically important changes in acute pain outcome measures: a validation study. J Pain Symptom Manage 2003; 25:406-411
35. Jensen MP. The validity and reliability of pain measures in adults with cancer. J Pain 2003; 4:2-21
36. Macbeth F, Stephens R. Palliative treatment for advanced non-small cell lung cancer. Hematol Oncol Clin North Am 2004; 18:115-130
37. Medley L, Cullen M. Best supportive care versus palliative chemotherapy in nonsmall-cell lung cancer. Curr Opin Oncol 2002; 14:384-388
38. Plunkett TA, Chrystal KF, Harper PG. Quality of life and the treatment of advanced lung cancer. Clin Lung Cancer 2003; 5:28-32
39. Spiro SG, Rudd RM, Souhami RL, et al. Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life. Thorax 2004; 59:828-836
40. Thongprasert S, Sanguanmitra P, Juthapan W, et al. Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy. Lung Cancer 1999; 24:17-24
41. Prommer E. Ketamine in palliative care: fast facts and concepts #132. Milwaukee, WI: End-of-life/Palliative Education Resource Center, Medical College of Wisconsin, 2005
42. Muers MF, Round CE. Palliation of symptoms in non-small cell lung cancer: a study by the Yorkshire Regional Cancer Organisation Thoracic Group. Thorax 1993; 48:339-343
43. Reuben DB, Mor V. Dyspnea in terminally ill cancer patients. Chest 1986; 89:234-236
44. Claessens MT, Lynn J, Zhong Z, et al. Dying with lung cancer or chronic obstructive pulmonary disease: insights from SUPPORT: Study To Understand Prognoses and Preferences for Outcomes and Risks of Treatments. J Am Geriatr Soc 2000; 48:S146-S153
45. Bruera E, Schmitz B, Pither J, et al. The frequency and correlates of dyspnea in patients with advanced cancer. J Pain Symptom Manage 2000; 19:357-362
46. Smith EL, Hann DM, Ahles TA, et al. Dyspnea, anxiety, body consciousness, and quality of life in patients with lung cancer. J Pain Symptom Manage 2001; 21:323-329
47. Jacobs LG. Managing respiratory symptoms at the end of life. Clin Geriatr Med 2003; 19:225-239
48. Dudgeon DJ, Lertzman M. Dyspnea in the advanced cancer patient. J Pain Symptom Manage 1998; 16:212-219
49. O'Driscoll M, Corner J, Bailey C. The experience of breathlessness in lung cancer. Eur J Cancer Care (Engl) 1999; 8:37-43
50. Bernhard J, Ganz PA. Psychosocial issues in lung cancer patients: part 1. Chest 1991; 99:216-223
51. Gift AG, Cahill CA. Psychophysiologic aspects of dyspnea in chronic obstructive pulmonary disease: a pilot study. Heart Lung 1990; 19:252-257
52. Kellner R, Samet J, Pathak D. Dyspnea, anxiety, and depression in chronic respiratory impairment. Gen Hosp Psychiatry 1992; 14:20-28
53. American Thoracic Society. Dyspnea: mechanisms, assessment, and management; a consensus statement. Am J Respir Crit Care Med 1999; 159:321-340
54. Mahler DA. Dyspnea. New York, NY: M Dekker, 1997
55. Bredin M, Corner J, Krishnasamy M, et al. Multicentre randomised controlled trial of nursing intervention for breathlessness in patients with lung cancer. BMJ 1999; 318:901-904
56. Corner J, Plant H, A'Hern R, et al. Non-pharmacological intervention for breathlessness in lung cancer. Palliat Med 1996; 10:299-305
57. Hately J, Laurence V, Scott A, et al. Breathlessness clinics within specialist palliative care settings can improve the quality of life and functional capacity of patients with lung cancer. Palliat Med 2003; 17:410-417
58. Escalante CP, Martin CG, Elting LS, et al. Dyspnea in cancer patients: etiology, resource utilization, and survival-implications in a managed care world. Cancer 1996; 78:1314-1319
59. Bruera E, de Stoutz N, Velasco-Leiva A, et al. Effects of oxygen on dyspnoea in hypoxaemic terminal-cancer patients. Lancet 1993; 342:13-14
60. Emtner M, Porszasz J, Burns M, et al. Benefits of supplemental oxygen in exercise training in nonhypoxemic chronic obstructive pulmonary disease patients. Am J Respir Crit Care Med 2003; 168:1034-1042
61. Ong KC, Kor AC, Chong WF, et al. Effects of inhaled furosemide on exertional dyspnea in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 169:1028-1033
62. Abratt RP, Willcox PA. The effect of irradiation on lung function and perfusion in patients with lung cancer. Int J Radiat Oncol Biol Phys 1995; 31:915-919
63. Boyd KJ, Kelly M. Oral morphine as symptomatic treatment of dyspnoea in patients with advanced cancer. Palliat Med 1997; 11:277-281
64. Zeppetella G. Nebulized morphine in the palliation of dyspnoea. Palliat Med 1997; 11:267-275
65. Muers MF. Opioids for dyspnoea. Thorax 2002; 57:922-923
66. Jennings AL, Davies AN, Higgins JP, et al. A systematic-review of the use of opioids in the management of dyspnoea. Thorax 2002; 57:939-944
67. Abernethy AP, Currow DC, Frith P, et al. Randomised, double blind, placebo controlled crossover trial of sustained reiease morphine for the management of refractory dyspnoea. BMJ 2003; 327:523-528
68. Cohen MH, Anderson AJ, Krasnow SH, et al. Continuous intravenous infusion of morphine for severe dyspnea. South Med J 1991; 84:229-234
69. Lang E, Jedeikin R. Acute respiratory depression as a complication of nebulised morphine. Can J Anaesth 1998; 45:60-62
70. Diacon AH, Bolliger CT. Functional evaluation before and after interventional bronchoscopy in patients with malignant central airway obstruction. Monaldi Arch Chest Dis 2001; 56:67-73
71. Ernst A, Feller-Kopman D, Becker HD, et al. Central airway obstruction. Am J Respir Crit Care Med 2004; 169:1278-1297
72. McMahon CC, Rainey L, Fulton B, et al. Central airway compression: anaesthetic and intensive care consequences. Anaesthesia 1997; 52:158-162
73. Wood DE, Liu YH, Vallieres E, et al. Airway stenting for malignant and benign tracheobronchial stenosis. Ann Thorac Surg 2003; 76:167-172; discussion 173-164
74. Prakash UBS. Bronchoscopy. In: Murray JF, Nadel JA, eds. Murray and Nadel's textbook of respiratory medicine. Philadelphia, PA: Saunders, 2005; 1617-1650
75. Santos RS, Raftopoulos Y, Keenan RJ, et al. Bronchoscopic palliation of primary lung cancer: single or multimodality therapy? Surg Endosc 2004; 18:931-936
76. Beamis JF Jr. Interventional pulmonology techniques for treating malignant large airway obstruction: an update. Curr Opin Pulm Med 2005; 11:292-295
77. Colt HG, Harrell JH. Therapeutic rigid bronchoscopy allows level of care changes in patients with acute respiratory failure from central airways obstruction. Chest 1997; 112:202-206
78. Shiraishi T, Kawahara K, Shirakusa T, et al. Stenting for airway obstruction in the carinal region. Ann Thorac Surg 1998; 66:1925-1929
79. Shivaram U, Finch P, Nowak P. Plastic endobronchial tubes in the management of life-threatening hemoptysis. Chest 1987; 92:1108-1110
80. Terada Y, Matsunobe S, Nemoto T, et al. Palliation of left main bronchus compression due to malignant tumor by intubation via a tracheostomy tube. Chest 1991; 100:1735-1737
81. Hautmann H, Gamarra F, Pfeifer KJ, et al. Fiberoptic bronchoscopic balloon dilatation in malignant tracheobronchial disease: indications and results. Chest 2001; 120:43-49
82. McArdle JR, Gildea T, Mehta AC. Balloon bronchoplasty: its indications, benefits, and complications. J Bronchol 2005; 12:123-127
83. Ball JB, Delaney JC, Evans CC, et al. Endoscopic bougie and balloon dilatation of multiple bronchial stenoses: 10 year follow up. Thorax 1991; 46:933-935
84. Hetzel MR, Smith SG. Endoscopic palliation of tracheobronchial malignancies. Thorax 1991; 46:325-333
85. Cavaliere S. Nd-Yag laser resection of tracheobronchial lesions. Panminerva Med 1986; 28:101-104
86. Cavaliere S, Foccoli P, Farina PL. Nd:YAG laser bronchoscopy: a five-year experience with 1,396 applications in 1,000 patients. Chest 1988; 94:15-21
87. Cavaliere S, Foccoli P, Toninelli C, et al. Nd:YAG laser therapy in lung cancer: an 11-year experience with 2,253 applications in 1,585 patients. J Bronchol 1994; 1:105-111
88. Cavaliere S, Venuta F, Foccoli P, et al. Endoscopic treatment of malignant airway obstructions in 2,008 patients. Chest 1996; 110:1536-1542
89. Lee P, Kupeli E, Mehta AC. Therapeutic bronchoscopy in lung cancer: laser therapy, electrocautery, brachytherapy, stents, and photodynamic therapy. Clin Chest Med 2002; 23:241-256
90. Petrou M, Kaplan D, Goldstraw P. Bronchoscopic diathermy resection and stent insertion: a cost effective treatment for tracheobronchial obstruction. Thorax 1993; 48:1156-1159
91. Sheski FD, Mathur PN. Cryotherapy, electrocautery, and brachytherapy. Clin Chest Med 1999; 20:123-138
92. Sheski FD, Mathur PN. Endobronchial electrosurgery: argon plasma coagulation and electrocautery. Semin Respir Crit Care Med 2004; 25:367-374
93. Sutedja G, van Kralingen K, Schramel FM, et al. Fibreoptic bronchoscopic electrosurgery under local anaesthesia for rapid palliation in patients with central airway malignancies: a preliminary report. Thorax 1994; 49:1243-1246
94. van Boxem AJ, Westerga J, Venmans BJ, et al. Photodynamic therapy, Nd-YAG laser and electrocautery for treating early-stage intraluminal cancer: which to choose? Lung Cancer 2001; 31:31-36
95. Homasson JP. Endobronchial electrocautery. Semin Respir Crit Care Med 1997; 18:535-543
96. van Boxem TJ, Venmans BJ, Schramel FM, et al. Radiographically occult lung cancer treated with fibreoptic bronchoscopic electrocautery: a pilot study of a simple and inexpensive technique. Eur Respir J 1998; 11:169-172
97. van Boxem TJ, Venmans BJ, van Mourik JC, et al. Bronchoscopic treatment of intraluminal typical carcinoid: a pilot study. J Thorac Cardiovasc Surg 1998; 116:402-406
98. Coulter TD, Mehta AC. The heat is on: impact of endobronchial electrosurgery on the need for Nd-YAG laser photoresection. Chest 2000; 118:516-521
99. Morice RC, Ece T, Ece F, et al. Endobronchial argon plasma coagulation for treatment of hemoptysis and neoplastic airway obstruction. Chest 2001; 119:781-787
100. Marasso A, Gallo E, Massaglia GM, et al. Cryosurgery in bronchoscopic treatment of tracheobronchial stenosis: indications, limits, personal experience. Chest 1993; 103:472-474
101. Mathur PN, Wolf KM, Busk MF, et al. Fiberoptic bronchoscopic cryotherapy in the management of tracheobronchial obstruction. Chest 1996; 110:718-723
102. Rodgers BM, Moazam F, Talbert JL. Endotracheal cryotherapy in the treatment of refractory airway strictures. Ann Thorac Surg 1983; 35:52-57
103. Maiwand MO, Homasson JP. Cryotherapy for tracheobronchial disorders. Clin Chest Med 1995; 16:427-443
104. Walsh DA, Maiwand MO, Nath AR, et al. Bronchoscopic cryotherapy for advanced bronchial carcinoma. Thorax 1990; 45:509-513
105. Maiwand MO, Evans JM, Beeson JE. The application of cryosurgery in the treatment of lung cancer. Cryobiology 2004; 48:55-61
106. Gejerman G, Mullokandov EA, Bagiella E, et al. Endobronchial brachytherapy and external-beam radiotherapy in patients with endobronchial obstruction and extrabronchial extension. Brachytherapy 2002; 1:204-210
107. Ofiara L, Roman T, Schwartzman K, et al. Local determinants of response to endobronchial high-dose rate brachytherapy in bronchogenic carcinoma. Chest 1997; 112:946-953
108. Schray MF, Mc-Dougall JC, Martinez A, et al. Management of malignant airway compromise with laser and low dose rate brachytherapy: the Mayo Clinic experience. Chest 1988; 93:264-269
109. Schray MF, McDougall JC, Martinez A, et al. Management of malignant airway obstruction: clinical and dosimetric considerations using an iridium-192 afterloading technique in conjunction with the neodymium-YAG laser. Int J Radiat Oncol Biol Phys 1985; 11:403-409
110. Villanueva AG, Lo TC, Beamis JF Jr. Endobronchial brachytherapy. Clin Chest Med 1995; 16:445-454
111. Bedwinek J, Petty A, Bruton C, et al. The use of high dose rate endobronchial brachytherapy to palliate symptomatic endobronchial recurrence of previously irradiated bronchogenic carcinoma. Int J Radiat Oncol Biol Phys 1992; 22:23-30
112. Nori D, Allison R, Kaplan B, et al. High dose-rate intraluminal irradiation in bronchogenic carcinoma: technique and results. Chest 1993; 104:1006-1011
113. Pisch J, Villamena PC, Harvey JC, et al. High dose-rate endobronchial irradiation in malignant airway obstruction. Chest 1993; 104:721-725
114. Seagren SL, Harrell JH, Horn RA. High dose rate intraluminal irradiation in recurrent endobronchial carcinoma. Chest 1985; 88:810-814
115. Sutedja T, Baris G, Zoetmulder F, et al. High dose rate brachytherapy improves resectability in squamous cell lung cancer. Chest 1992; 102:308-309
116. Burt PA, O'Driscoll BR, Notley HM, et al. Intraluminal irradiation for the palliation of lung cancer with the high dose rate Micro-Selectron. Thorax 1990; 45:765-768
117. Chang LF, Horvath J, Peyton W, et al. High dose rate afterloading intraluminal brachytherapy in malignant airway obstruction of lung cancer. Int J Radiat Oncol Biol Phys 1994; 28:589-596
118. Collins SW, Burt PA, Barber PV, et al. High dose rate intraluminal radiotherapy for carcinoma of the bronchus: outcome of treatment of 406 patients. Radiother Oncol 1994; 33:31-40
119. Collins SW, Burt PA, Barber PV, et al. Long-term survival and symptom palliation in small primary bronchial carcinomas following treatment with intraluminal radiotherapy alone. Clin Oncol (R Coll Radiol) 1996; 8:239-246
120. Huber RM, Fischer R, Hautmann H, et al. Palliative endobronchial brachytherapy for central lung tumors: a prospective, randomized comparison of two fractionation schedules. Chest 1995; 107:463-470
121. Langendijk H, de Jong J, Tjwa M, et al. External irradiation versus external irradiation plus endobronchial brachytherapy in inoperable non-small cell lung cancer: a prospective randomized study. Radiother Oncol 2001; 58:257-268
122. Mehta MP, Shahabi S, Jarjour NN, et al. Endobronchial irradiation for malignant airway obstruction. Int J Radiat Oncol Biol Phys 1989; 17:847-851
123. Speiser BL, Spratling L. Remote afterloading brachytherapy for the local control of endobronchial carcinoma. Int J Radiat Oncol Biol Phys 1993; 25:579-587
124. Anacak Y, Mogulkoc N, Ozkok S, et al. High dose rate endobronchial brachytherapy in combination with external beam radiotherapy for stage III non-small cell lung cancer. Lung Cancer 2001; 34:253-259
125. Furukawa K, Kato H, Konaka C, et al. Locally recurrent central-type early stage lung cancer < 1.0 cm in diameter after complete remission by photodynamic therapy. Chest 2005; 128:3269-3275
126. Cortese DA, Edell ES, Kinsey JH. Photodynamic therapy for early stage squamous cell carcinoma of the lung. Mayo Clin Proc 1997; 72:595-602
127. Edell ES, Cortese DA. Bronchoscopic phototherapy with hematoporphyrin derivative for treatment of localized bronchogenic carcinoma: a 5-year experience. Mayo Clin Proc 1987; 62:8-14
128. Freitag L, Ernst A, Thomas M, et al. Sequential photodynamic therapy (PDT) and high dose brachytherapy for endobronchial tumour control in patients with limited bronchogenic carcinoma. Thorax 2004; 59:790-793
129. Ernst A, Freitag L, Feller-Kopman D, et al. Photodynamic therapy for endobronchial obstruction is safely performed with flexible bronchoscopy. J Bronchol 2003; 10:260-263
130. Moghissi K, Dixon K, Stringer M, et al. The place of bronchoscopic photodynamic therapy in advanced unresectable lung cancer: experience of 100 cases. Eur J Cardiothorac Surg 1999; 15:1-6
131. Maziak DE, Markman BR, MacKay JA, et al. Photodynamic therapy in nonsmall cell lung cancer: a systematic review. Ann Thorac Surg 2004; 77:1484-1491
132. Bolliger CT, Heitz M, Hauser R, et al. An airway Wallstent for the treatment of tracheobronchial malignancies. Thorax 1996; 51:1127-1129
133. Madden BP, Park JE, Sheth A. Medium-term follow-up after deployment of Ultraflex expandable metallic stents to manage endobronchial pathology. Ann Thorac Surg 2004; 78:1898-1902
134. Monnier P, Mudry A, Stanzel F, et al. The use of the covered Wallstent for the palliative treatment of inoperable tracheobronchial cancers: a prospective, multicenter study. Chest 1996; 110:1161-1168
135. Saad CP, Murthy S, Krizmanich G, et al. Self-expandable metallic airway stents and flexible bronchoscopy: long-term outcomes analysis. Chest 2003; 124:1993-1999
136. Stockton PA, Ledson MJ, Hind CR, et al. Bronchoscopic insertion of Gianturco stents for the palliation of malignant lung disease: 10 year experience. Lung Cancer 2003; 42:113-117
137. Walser EM. Stent placement for tracheobronchial disease. Eur J Radiol 2005; 55:321-330
138. Dutau H, Toutblanc B, Lamb C, et al. Use of the Dumon Y-stent in the management of malignant disease involving the carina: a retrospective review of 86 patients. Chest 2004; 126:951-958
139. Miyazawa T, Yamakido M, Ikeda S, et al. Implantation of ultraflex nitinol stents in malignant tracheobronchial stenoses. Chest 2000; 118:959-965
140. Herth F, Becker HD, LoCicero J III, et al. Successful bronchoscopic placement of tracheobronchial stents without fluoroscopy. Chest 2001; 119:1910-1912
141. Witt C, Dinges S, Schmidt B, et al. Temporary tracheobronchial stenting in malignant stenoses. Eur J Cancer 1997; 33:204-208
142. Dumon JF. A dedicated tracheobronchial stent. Chest 1990; 97:328-332
143. Dumon JF, Cavaliere S, Diaz-Jimenez P, et al. Seven-year experience with the Dumon prosthesis. J Bronchol 1996; 3:6-10
144. Homasson JP, Renault P, Angebault M, et al. Bronchoscopic cryotherapy for airway strictures caused by tumors. Chest 1986; 90:159-164
145. de Perrot M, Fadel E, Mercier O, et al. Long-term results after carinal resection for carcinoma: does the benefit warrant the risk? J Thorac Cardiovasc Surg 2006; 131:81-89
146. Pezzetta E, Meyer A, El Lamaa Z, et al. Left-sided modified Kergin carinoplasty as an alternative to carinal resection for centrally located non-small cell lung cancer pretreated by radiochemotherapy. J Thorac Cardiovasc Surg 2005; 130:1218-1219
147. Regnard JF, Perrotin C, Giovannetti R, et al. Resection for tumors with carinal involvement: technical aspects, results, and prognostic factors. Ann Thorac Surg 2005; 80:1841-1846
148. Vaaler AK, Forrester JM, Lesar M, et al. Obstructive atelectasis in patients with small cell lung cancer: incidence and response to treatment. Chest 1997; 111:115-120
149. Doona M, Walsh D. Benzonatate for opioid-resistant cough in advanced cancer. Palliat Med 1998; 12:55-58
150. Moroni M, Porta C, Gualtieri G, et al. Inhaled sodium cromoglycate to treat cough in advanced lung cancer patients. Br J Cancer 1996; 74:309-311
151. Luporini G, Barni S, Marchi E, et al. Efficacy and safety of levodropropizine and dihydrocodeine on nonproductive cough in primary and metastatic lung cancer. Eur Respir J 1998; 12:97-101
152. Jassem J, Krzakowski M, Roszkowski K, et al. A phase II study of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer: clinical outcomes and quality of life. Lung Cancer 2002; 35:73-79
153. Thatcher N, Jayson G, Bradley B, et al. Gemcitabine: symptomatic benefit in advanced non-small cell lung cancer. Semin Oncol 1997; 24:S8-6-S8-12
154. Gogas H, Lofts FJ, Evans TR, et al. Outpatient treatment with epirubicin and oral etoposide in patients with small-cell lung cancer. Br J Cancer 1997; 76:639-642
155. Hickish TF, Smith IE, Nicolson MC, et al. A pilot study of MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in small-cell lung cancer. Br J Cancer 1998; 77:1966-1970
156. White SC, Lorigan P, Middleton MR, et al. Randomized phase II study of cyclophosphamide, doxorubicin, and vincristine compared with single-agent carboplatin in patients with poor prognosis small cell lung carcinoma. Cancer 2001; 92:601-608
157. Andrews NC, Curtis GM, Klassen KP, et al. Palliative vagatomy for nonresectable bronchogenic carcinoma. Ill Med J 1956; 110:167-171
158. Medical Research Council Lung Cancer Working Party. Inoperable non-small-cell lung cancer (NSCLC): a Medical Research Council randomised trial of palliative radiotherapy with two fractions or ten fractions; report to the Medical Research Council by its Lung Cancer Working Party. Br J Cancer 1991; 63:265-270
159. Medical Research Council Lung Cancer Working Party. A Medical Research Council (MRC) randomised trial of palliative radiotherapy with two fractions or a single fraction in patients with inoperable non-small-cell lung cancer (NSCLC) and poor performance status. Br J Cancer 1992; 65:934-941
160. Boxem T, Muller M, Venmans B, et al. Nd-YAG laser vs bronchoscopic electrocautery for palliation of symptomatic airway obstruction: a cost-effectiveness study. Chest 1999; 116:1108-1112
161. Homsi J, Walsh D, Nelson KA. Important drugs for cough in advanced cancer. Support Care Cancer 2001; 9:565-574
162. Hoegler D. Radiotherapy for palliation of symptoms in incurable cancer. Curr Probl Cancer 1997; 21:129-183
163. Sze WM, Shelley MD, Held I, et al. Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy: a systematic review of randomised trials. Clin Oncol (R Coll Radiol) 2003; 15:345-352
164. Berenson JR. Recommendations for zoledronic acid treatment of patients with bone metastases. Oncologist 2005; 10:52-62
165. Delea T, Langer C, McKiernan J, et al. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer. Oncology 2004; 67:390-396
166. Rosen LS, Gordon D, Tehekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial; the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003; 21:3150-3157
167. Shucai Z, Guimei L, Fanbin H: A clinical trial of bonin in bone metastases of lung cancer. Chin J Clin Oncol 1999; 26:445-447
168. Bauman G, Charette M, Reid R, et al. Radiopharmaceuticals for the palliation of painful bone metastasis-a systemic review. Radiother Oncol 2005; 75:258-270
169. Haentjens P, Casteleyn PP, Opdecam P. Evaluation of impending fractures and indications for prophylactic fixation of metastases in long bones: review of the literature. Acta Orthop Belg 1993; 59(suppl):6-11
170. Broos P, Reynders P, van den Bogert W, et al. Surgical treatment of metastatic fracture of the femur improvement of quality of life. Acta Orthop Belg 1993; 59(suppl):52-56
171. Jacofsky DJ, Haidukewych GJ. Management of pathologic fractures of the proximal femur: state of the art. J Orthop Trauma 2004; 18:459-469
172. Newman SJ, Hansen HH. Proceedings: frequency, diagnosis, and treatment of brain metastases in 247 consecutive patients with bronchogenic carcinoma. Cancer 1974; 33:492-496
173. Hirsch FR, Paulson OB, Hansen HH, et al. Intracranial metastases in small cell carcinoma of the lung: prognostic aspects. Cancer 1983; 51:529-533
174. Andrews RJ, Gluck DS, Konchingeri RH. Surgical resection of brain metastases from lung cancer. Acta Neurochir (Wien) 1996; 138:382-389
175. Kelly K, Bunn PA Jr. Is it time to reevaluate our approach to the treatment of brain metastases in patients with non-small cell lung cancer? Lung Cancer 1998; 20:85-91
176. Cairncross JG, Kim JH, Posner JB. Radiation therapy for brain metastases. Ann Neurol 1980; 7:529-541
177. Coia LR, Aaronson N, Linggood R, et al. A report of the consensus workshop panel on the treatment of brain metastases. Int J Radiat Oncol Biol Phys 1992; 23:223-227
178. French LA, Galicich JH. The use of steroids for control of cerebral edema. Clin Neurosurg 1964; 10:212-223
179. Shapiro WR. Intracranial neoplasms. In: Rosenberg RN, ed, Comprehensive neurology. New York, NY: Raven Press, 1991; 157-200
180. Weiss HD. Neoplasms. In: Samuels MA, ed. Manual of neurology: diagnosis and therapy. Boston, MA: Little, Brown, 1991; 213-239
181. Weissman DE, Dufer D, Vogel V, et al. Corticosteroid toxicity in neuro-oncology patients. J Neurooncol 1987; 5:125-128
182. Vecht CJ, Hovestadt A, Verbiest HB, et al. Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors: a randomized study of doses of 4, 8, and 16 rag per day. Neurology 1994; 44:675-680
183. Weissman DE, Janjan NA, Erickson B, et al. Twice-daily tapering dexamethasone treatment during cranial radiation for newly diagnosed brain metastases. J Neurooncol 1991; 11:235-239
184. Wolfson AH, Snodgrass SM, Schwade JG, et al. The role of steroids in the management of metastatic carcinoma to the brain: a pilot prospective trial. Am J Clin Oncol 1994; 17:234-238
185. Arriagada R, Le Chevalier T, Borie F, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. J Natl Cancer Inst 1995; 87:183-190
186. Komaki R. Prophylactic cranial irradiation for small cell carcinoma of the lung. Cancer Treat Symp 1985; 2:35-39
187. Diener-West M, Dobbins TW, Phillips TL, et al. Identification of an optimal subgroup for treatment evaluation of patients with brain metastases using RTOG study 7916. Int J Radiat Oncol Biol Phys 1989; 16:669-673
188. Lester JF, MacBeth FR, Coles B. Prophylactic cranial irradiation for preventing brain metastases in patients undergoing radical treatment for non-small-cell lung cancer: a Cochrane Review. Int J Radiat Oncol Biol Phys 2005; 63:690-694
189. Rock JP, Haines S, Recht L, et al. Practice parameters for the management of single brain metastatsis. Neurosurg Focus, 2000; 1-9
190. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990; 322:494-500
191. Vecht CJ, Haaxma-Reiche H, Noordijk EM, et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol 1993; 33:583-590
192. Mintz AH, Kestle J, Rathbone MP, et al. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer 1996; 78:1470-1476
193. Patchell RA, Tibbs PA, Regine WF, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 1998; 280:1485-1489
194. Borgelt B, Gelber R, Kramer S, et al. The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1980; 6:1-9
195. Kurtz JM, Gelber R, Brady LW, et al. The palliation of brain metastases in a favorable patient population: a randomized clinical trial by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1981; 7:891-895
196. Patchell RA, Regine WF. The rationale for adjuvant whole brain radiation therapy with radiosurgery in the treatment of single brain metastases. Technol Cancer Res Treat 2003; 2:111-115
197. Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery hoost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 2004; 363:1665-1672
198. Sneed PK, Suh JH, Goetsch SJ, et al. A multi-institutional review of radiosurgery alone vs. radiosurgery with whole brain radiotherapy as the initial management of brain metastases. Int J Radiat Oncol Biol Phys 2002; 53:519-526
199. Adler JR, Cox RS, Kaplan I, et al. Stereotactic radiosurgical treatment of brain metastases. J Neurosurg 1992; 76:444-449
200. Alexander E III, Moriarty TM, Davis RB, et al. Stereotactic radiosurgery for the definitive, noninvasive treatment of brain metastases. J Natl Cancer Inst 1995; 87:34-40
201. Flickinger JC, Kondziolka D, Lunsford LD, et al. A multi-institutional experience with stereotactic radiosurgery for solitary brain metastasis. Int J Radiat Oncol Biol Phys 1994; 28:797-802
202. Shirato H, Takamura A, Tomita M, et al. Stereotactic irradiation without whole-brain irradiation for single brain metastasis. Int J Radiat Oncol Biol Phys 1997; 37:385-391
203. Zouhair A, Tercier PA, Fankhauser H, et al. Stereotaxic radiotherapy of brain metastases: experiences in Lausanne. Schweiz Med Wochenschr 1997; 127:1652-1656
204. Muacevic A, Kreth FW, Horstmann GA, et al. Surgery and radiotherapy compared with gamma knife radiosurgery in the treatment of solitary cerebral metastases of small diameter. J Neurosurg 1999; 91:35-43
205. Li B, Yu J, Suntharalingam M, et al. Comparison of three treatment options for single brain metastasis from lung cancer. Int J Cancer 2000; 90:37-45
206. Kondziolka D, Patel A, Lunsford LD, et al. Stereotactic-radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Radiat Oncol Biol Phys 1999; 45:427-434
207. Hoffman R, Sneed PK, McDermott MW, et al. Radiosurgery for brain metastases from primary lung carcinoma. Cancer J 2001; 7:121-131
208. Langer CJ, Mehta MP. Current management of brain metastases, with a focus on systemic options. J Clin Oncol 2005; 23:6207-6219
209. Schuette W. Treatment of brain metastases from lung cancer: Chemotherapy. Lung Cancer 2004; 45(suppl):S253-S257
210. Taimur S, Edelman MJ. Treatment options for brain metastases in patients with non-small-cell lung cancer. Curr Oncol Rep 2003; 5:342-346
211. Robinet G, Thomas P, Breton JL, et al. Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: groupe Francais de Pneumo-Cancerologie (GFPC) Protocol 95-1. Ann Oncol 2001; 12:59-67
212. Kim DY, Lee KW, Yun T, et al. Efficacy of platinum-based chemotherapy after cranial radiation in patients with brain metastasis from non-small cell lung cancer. Oncol Rep 2005; 14:207-211
213. Antonadou D, Coliarakis N, Paraskevaidis M, et al. Whole brain radiotherapy alone or in combination with temozolomide (TMZ) for brain metastases: a phase III study. Int J Radiat Oncol Biol Phys 2002; 54(suppl):93-94
214. Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997; 37:745-751
215. Turner S, Marosszeky B, Timms I, et al. Malignant spinal cord compression: a prospective evaluation. Int J Radiat Oncol Biol Phys 1993; 26:141-146
216. Rodichok LD, Harper GR, Ruckdeschel JC, et al. Early diagnosis of spinal epidural metastases. Am J Med 1981; 70:1181-1188
217. Ruckdeschel JC. Early detection and treatment of spinal cord compression. Oncology (Williston Park) 2005; 19:81-86
218. Loblaw DA, Laperriere NJ, Perry J, et al. Malignant extradural spinal cord compression: diagnosis and management; evidence summary report No. 9-9. Cancer Ontario Practice Guideline Initiative. Available at: www.cancercare.on. ca/pdf/pebc9-9esf.pdf. Accessed August 31, 2007
219. Sorensen S, Helweg-Larsen S, Mouridsen H, et al. Effect of high-dose dexamethasone in carcinomatous metastatic spinal cord compression treated with radiotherapy: a randomised trial. Eur J Cancer 1994; 30A:22-27
220. Jenis LG, Dunn EJ, An HS. Metastatic disease of the cervical spine. A review. Clin Orthop Relat Res 1999; 89-103
221. Hamilton AJ, Lulu BA, Fosmire H, et al. LINAC-based spinal stereotactic radiosurgery. Stereotact Funct Neurosurg 1996; 66:1-9
222. Ryu S, Fang Yin F, Rock J, et al. Image-guided and intensity-modulated radiosurgery for patients with spinal metastasis. Cancer 2003; 97:2013-2018
223. Klimo P Jr, Schmidt MH. Surgical management of spinal metastases. Oncologist 2004; 9:188-196
224. Fourney DR, Schomer DF, Nader R, et al. Percutaneous vertebroplasty and kyphoplasty for painful vertebral body fractures in cancer patients. J Neurosurg 2003; 98:21-30
225. Han PP, Kenny K, Dickman CA. Thoracoscopic approaches to the thoracic spine: experience with 241 surgical procedures. Neurosurgery 2002; 51:S88-S95
226. McLain RF. Spinal cord decompression: an endoscopically assisted approach for metastatic tumors. Spinal Cord 2001; 39:482-487
227. Patchell RA, Tibbs PA, Regine WF, et al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet 2005; 366:643-648
228. Miller RR, McGregor DH. Hemorrhage from carcinoma of the lung. Cancer 1980; 46:200-205
229. Corner J, Hopkinson J, Fitzsimmons D, et al. Is late diagnosis of lung cancer inevitable? Interview study of patients' recollections of symptoms before diagnosis. Thorax 2005; 60:314-319
230. Corey R, Hla KM. Major and massive hemoptysis: reassessment of conservative management. Am J Med Sci 1987; 294:301-309
231. Cahill BC, Ingbar DH. Massive hemoptysis: assessment and management. Clin Chest Med 1994; 15:147-167
232. Jean-Baptiste E. Clinical assessment and management of massive hemoptysis. Crit Care Med 2000; 28:1642-1647
233. Jean-Baptiste E. Clinical assessment and management of massive hemoptysis [letter]. Crit Care Med 2001; 29:1098
234. Strange C. Double-lumen endotracheal tubes. Clin Chest Med 1991; 12:497-506
235. Ong TH, Eng P. Massive hemoptysis requiring intensive care. Intensive Care Med 2003; 29:317-320
236. Conlan AA, Hurwitz SS. Management of massive haemoptysis with the rigid bronchoscope and cold saline lavage. Thorax 1980; 35:901-904
237. Sahebjami H. Iced saline lavage during bronchoscopy [letter]. Chest 1976; 69:131-132
238. Gottlieb LS, Hillberg R. Endobronchial tamponade therapy for intractable hemoptysis. Chest 1975; 67:482-483
239. Hiebert CA. Balloon catheter control of life-threatening hemoptysis. Chest 1974; 66:308-309
240. Saw EC, Gottlieb LS, Yokoyama T, et al. Flexible fiberoptic bronchoscopy and endobronchial tamponade in the management of massive hemoptysis. Chest 1976; 70:589-591
241. Swersky RB, Chang JB, Wisoff BG, et al. Endobronchial balloon tamponade of hemoptysis in patients with cystic fibrosis. Ann Thorac Surg 1979; 27:262-264
242. Valipour A, Kreuzer A, Koller H, et al. Bronchoscopy-guided topical hemostatic tamponade therapy for the management of life-threatening hemoptysis. Chest 2005; 127:2113-2118
243. Knott-Craig CJ, Oostuizen JG, Rossouw G, et al. Management and prognosis of massive hemoptysis: recent experience with 120 patients. J Thorac Cardiovasc Surg 1993; 105:394-397
244. Mal H, Rullon I, Mellot F, et al. Immediate and long-term results of bronchial artery embolization for life-threatening hemoptysis. Chest 1999; 115:996-1001
245. Osaki S, Nakanishi Y, Wataya H, et al. Prognosis of bronchial artery embolization in the management of hemoptysis. Respiration 2000; 67:412-416
246. White RI Jr. Bronchial artery embolotherapy for control of acute hemoptysis: analysis of outcome. Chest 1999; 115:912-915
247. Jain PR, Dedhia HV, Lapp NL, et al. Nd:YAG laser followed by radiation for treatment of malignant airway lesions. Lasers Surg Med 1985; 5:47-53
248. Cohen S, Hossain SA. Primary carcinoma of the lung: a review of 417 histologically proved cases. Dis Chest 1966; 49:67-74
249. Emerson GL, Emerson MS, Sherwood CE. The natural history of carcinoma of the lung. J Thorac Surg 1959; 37:291-304
250. Johnston WW. The malignant pleural effusion: a review of cytopathologic diagnoses of 584 specimens from 472 consecutive patients. Cancer 1985; 56:905-909
251. Anthony VB, Lodden Kemper R, Astoul P, et al. Management of malignant pleural effusions. Am J Respir Crit Care Med 2000; 162:1987-2001
252. Chernow B, Sahn SA. Carcinomatous involvement of the pleura: an analysis of 96 patients. Am J Med 1977; 63:695-702
253. Agusti AG, Cardus J, Roca J, et al. Ventilation-perfusion mismatch in patients with pleural effusion: effects of thoracentesis. Am J Respir Crit Care Med 1997; 156:1205-1209
254. Brown NE, Zamel N, Aberman A. Changes in pulmonary mechanics and gas exchange following thoracocentesis. Chest 1978; 74:540-542
255. Estenne M, Yernault JC, De Troyer A. Mechanism of relief of dyspnea after thoracocentesis in patients with large pleural effusions. Am J Med 1983; 74:813-819
256. Karetzky MS, Kothari GA, Fourre JA, et al. Effect of thoracentesis on arterial oxygen tension. Respiration 1978; 36:96-103
257. Krell WS, Rodarte JR. Effects of acute pleural effusion on respiratory system mechanics in dogs. J Appl Physiol 1985; 59:1458-1463
258. Light RW, Stansbury DW, Brown SE. The relationship between pleural pressures and changes in pulmonary function after therapeutic thoracentesis. Am Rev Respir Dis 1986; 133:658-661
259. Lan RS, Lo SK, Chuang ML, et al. Elastance of the pleural space: a predictor for the outcome of pleurodesis in patients with malignant pleural effusion. Ann Intern Med 1997; 126:768-774
260. Light RW, Jenkinson SG, Minh VD, et al. Observations on pleural fluid pressures as fluid is withdrawn during thoracentesis. Am Rev Respir Dis 1980; 121:799-804
261. Chen YM, Shih JF, Yang KY, et al. Usefulness of pig-tail catheter for palliative drainage of malignant pleural effusions in cancer patients. Support Care Cancer 2000; 8:423-426
262. Pien GW, Gant MJ, Washam CL, et al. Use of an implantable pleural catheter for trapped lung syndrome in patients with malignant pleural effusion. Chest 2001; 119:1641-1646
263. Pollak JS, Burdge CM, Rosenblatt M, et al. Treatment of malignant pleural effusions with tunneled long-term drainage catheters. J Vasc Interv Radiol 2001; 12:201-208
264. Smart JM, Tung KT. Initial experiences with a long-term indwelling tunnelled pleural catheter for the management of malignant pleural effusion. Clin Radiol 2000; 55:882-884
265. Tremblay A, Michaud G. Single-center experience with 250 tunnelled pleural catheter insertions for malignant pleural effusion. Chest 2006; 129:362-368
266. van den Toorn LM, Schaap E, Surmont VF, et al. Management of recurrent malignant pleural effusions with a chronic indwelling pleural catheter. Lung Cancer 2005; 50:123-127
267. Verfaillie G, Herreweghe RV, Lamote J, et al. Use of a Port-a-Cath system in the home setting for the treatment of symptomatic recurrent malignant pleural effusion. Eur J Cancer Care (Engl) 2005; 14:182-184
268. Putnam JB Jr., Walsh GL, Swisher SG, et al. Outpatient management of malignant pleural effusion by a chronic indwelling pleural catheter. Ann Thorac Surg 2000; 69:369-375
269. Walker-Renard PB, Vaughan LM, Sahn SA. Chemical pleurodesis for malignant pleural effusions. Ann Intern Med 1994; 120:56-64
270. Sartori S, Tassinari D, Ceccotti P, et al. Prospective randomized trial of intrapleural bleomycin versus interferon α-2b via ultrasound-guided small-bore chest tube in the palliative treatment of malignant pleural effusions. J Clin Oncol 2004; 22:1228-1233
271. Ishida A, Miyazawa T, Miyazu Y, et al. Intrapleural cisplatin and OK432 therapy for malignant pleural effusion caused by non-small cell lung cancer. Respirology 2006; 11:90-97
272. Ukale V, Agrenius V, Hillerdal G, et al. Pleurodesis in recurrent pleural effusions: a randomized comparison of a classical and a currently popular drug. Lung Cancer 2004; 43:323-328
273. Gebbia N, Mannino R, Di Dino A, et al. Intracavitary treatment of malignant pleural and peritoneal effusions in cancer patients. Anticancer Res 1994; 14:739-745
274. Goldman CA, Skinnider LF, Maksymiuk AW. Interferon instillation for malignant pleural effusions. Ann Oncol 1993; 4:141-145
275. Rosso R, Rimoldi R, Salvati F, et al. Intrapleural natural beta interferon in the treatment of malignant pleural effusions. Oncology 1988; 45:253-256
276. Wilkins HE III, Connolly MM, Grays P, et al. Recombinant interferon α-2b in the management of malignant pleural effusions. Chest 1997; 111:1597-1599
277. North SA, Au HJ, Halls SB, et al. A randomized, phase III, double-blind, placebo-controlled trial of intrapleural instillation of methylprednisolone acetate in the management of malignant pleural effusion. Chest 2003; 123:822-827
278. Dikensoy O, Light RW. Alternative widely available, inexpensive agents for pleurodesis. Curr Opin Pulm Med 2005; 11:340-344
279. Paschoalini Mda S, Vargas FS, Marchi E, et al. Prospective randomized trial of silver nitrate vs talc slurry in pleurodesis for symptomatic malignant pleural effusions. Chest 2005; 128:684-689
280. Diacon AH, Wyser C, Bolliger CT, et al. Prospective randomized comparison of thoracoscopic talc poudrage under local anesthesia versus bleomycin instillation for pleurodesis in malignant pleural effusions. Am J Respir Crit Care Med 2000; 162:1445-1449
281. Groth G, Gatzemeier U, Haussingen K, et al. Intrapleural palliative treatment of malignant pleural effusions with mitoxantrone versus placebo (pleural tube alone). Ann Oncol 1991; 2:213-215
282. Kennedy L, Rusch VW, Strange C, et al. Pleurodesis using talc slurry. Chest 1994; 106:342-346
283. Marrazzo A, Noto A, Casa L, et al. Video-thoracoscopic surgical pleurodesis in the management of malignant pleural effusion: the importance of an early intervention. J Pain Symptom Manage 2005; 30:75-79
284. Webb WR, Ozmen V, Moulder PV, et al. Iodized talc pleurodesis for the treatment of pleural effusions. J Thorac Cardiovasc Surg 1992; 103:881-885; discussion 885-886
285. Weissberg D, Ben-Zeev I. Talc pleurodesis: experience with 360 patients. J Thorac Cardiovasc Surg 1993; 106:689-695
286. Shaw P, Agarwal R. Pleurodesis for malignant pleural effusions. Cochrane Database of Systematic Reviews 2006; 1
287. Antony VB, Loddenkemper R, Astoul P, et al. Management of malignant pleural effusions. Eur Respir J 2001; 18:402-419
288. Campos JR, Werebe EC, Vargas FS, et al. Respiratory failure due to insufflated talc. Lancet 1997; 349:251-252
289. Light RW. Talc should not be used for pleurodesis. Am J Respir Crit Care Med 2000; 162:2024-2026
290. Rehse DH, Aye RW, Florence MG. Respiratory failure following talc pleurodesis. Am J Surg 1999; 177:437-440
291. Rinaldo JE, Owens GR, Rogers RM. Adult respiratory distress syndrome following intrapleural instillation of talc. J Thorac Cardiovasc Surg 1983; 85:523-526
292. Sahn SA. Talc should be used for pleurodesis. Am J Respir Crit Care Med 2000; 162:2023-2024; discussion 2026
293. Yim AP, Chan AT, Lee TW, et al. Thoracoscopic talc insufflation versus talc slurry for symptomatic malignant pleural effusion. Ann Thorac Surg 1996; 62:1655-1658
294. Dresler CM, Olak J, Herndon JE II, et al. Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. Chest 2005; 127:909-915
295. Lee KA, Harvey JC, Reich H, et al. Management of malignant pleural effusions with pleuroperitoneal shunting. J Am Coll Surg 1994; 178:586-588
296. Petrou M, Kaplan D, Goldstraw P. Management of recurrent malignant pleural effusions: the complementary role talc pleurodesis and pleuroperitoneal shunting. Cancer 1995; 75:801-805
297. Ponn RB, Blancaflor J, D'Agostino RS, et al. Pleuroperitoneal shunting for intractable pleural effusions. Ann Thorac Surg 1991; 51:605-609
298. Pope AR, Joseph JH. Pleuroperitoneal shunt for pneumonectomy cavity malignant effusion. Chest 1989; 96:686-688
299. Reich H, Beattie EJ, Harvey JC. Pleuroperitoneal shunt for malignant pleural effusions: a one-year experience. Semin Surg Oncol 1993; 9:160-162
300. Schulze M, Boehle AS, Kurdow R, et al. Effective treatment of malignant pleural effusion by minimal invasive thoracic surgery: thoracoscopic talc pleurodesis and pleuroperitoneal shunts in 101 patients. Ann Thorac Surg 2001; 71:1809-1812
301. Gene O, Petrou M, Ladas G, et al. The long-term morbidity of pleuroperitoneal shunts in the management of recurrent malignant effusions. Eur J Cardiothorac Surg 2000; 18:143-146
302. Davies CW, Traill ZC, Gleeson FV, et al. Intrapleural streptokinase in the management of malignant multiloculated pleural effusions. Chest 1999; 115:729-733
303. Gilkeson RC, Silverman P, Haaga JR. Using urokinase to treat malignant pleural effusions. AJR Am J Roentgenol 1999; 173:781-783
304. Livingston RB, McCracken JD, Trauth CJ, et al. Isolated pleural effusion in small cell lung carcinoma: favorable prognosis: a review of the Southwest Oncology Group experience. Chest 1982; 81:208-211
305. Xaubet A, Diumenjo MC, Marin A, et al. Characteristics and prognostic value of pleural effusions in non-Hodgkin's lymphomas. Eur J Respir Dis 1985; 66:135-140
306. Su WC, Lai WW, Chen HH, et al. Combined intrapleural and intravenous chemotherapy, and pulmonary irradiation, for treatment of patients with lung cancer presenting with malignant pleural effusion: a pilot study. Oncology 2003; 64:18-24
307. Bal S, Hasan SS. Thoracoscopic management of malignant pleural effusion. Int Surg 1993; 78:324-327
308. Boutin C, Rey F, Gouvernet J, et al. Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients: part 2; prognosis and staging. Cancer 1993; 72:394-404
309. Fry WA, Khandekar JD. Parietal pleurectomy for malignant pleural effusion. Ann Surg Oncol 1995; 2:160-164
310. Gasparri R, Leo F, Veronesi G, et al. Video-assisted management of malignant pleural effusion in breast carcinoma. Cancer 2006; 106:271-276
311. Hassan SS. Thoracoscopic management of malignant pleural effusion: technique, complications and prevention. Surg Technol Int 2000; 8:179-182
312. LoCicero J III. Thoracoscopic management of malignant pleural effusion. Ann Thorac Surg 1993; 56:641-643
313. Love D, White D, Kiroff G. Thoracoscopic talc pleurodesis for malignant pleural effusion. ANZ J Surg 2003; 73:19-22
314. Viallat JR, Rey F, Astoul P, et al. Thoracoscopic talc poudrage pleurodesis for malignant effusions: a review of 360 cases. Chest 1996; 110:1387-1393
315. Waller DA, Morritt GN, Forty J. Video-assisted thoracoscopic pleurectomy in the management of malignant pleural effusion. Chest 1995; 107:1454-1456
316. Menzies R, Charbonneau M. Thoracoscopy for the diagnosis of pleural disease. Ann Intern Med 1991; 114:271-276
317. Yim AP, Chung SS, Lee TW, et al. Thoracoscopic management of malignant pleural effusions. Chest 1996; 109:1234-1238
318. Pulsiripunya C, Youngchaiyud P, Pushpakom R, et al. The efficacy of doxycycline as a pleural sclerosing agent in malignant pleural effusion: a prospective study. Respirology 1996; 1:69-72
319. Robinson LA, Fleming WH, Galbraith TA. Intrapleural doxycycline control of malignant pleural effusions. Ann Thorac Surg 1993; 55:1115-1121
320. Ostler PJ, Clarke DP, Watkinson AF, et al. Superior vena cava obstruction: a modern management strategy. Clin Oncol (R Coll Radiol) 1997; 9:83-89
321. Bechtold RE, Wolfman NT, Karstaedt N, et al. Superior vena caval obstruction: detection using CT. Radiology 1985; 157:485-487
322. Rowell NP, Gleeson FV. Steroids, radiotherapy, chemotherapy and stents for superior vena caval obstruction in carcinoma of the bronchus: a systematic review. Clin Oncol (R Coll Radiol) 2002; 14:338-351
323. Baker GL, Barnes HJ. Superior vena cava syndrome: etiology, diagnosis, and treatment. Am J Crit Care 1992; 1:54-64
324. Gauden SJ. Superior vena cava syndrome induced by bronchogenic carcinoma: is this an oncological emergency? Australas Radiol 1993; 37:363-366
325. Schraufnagel DE, Hill R, Leech JA, et al. Superior vena caval obstruction: is it a medical emergency? Am J Med 1981; 70:1169-1174
326. Muers MF. Quality of life and symptom control. In: Spiro S, ed. Lung cancer. Sheffield, UK: European Respiratory Society Journals, 2001; 305-329
327. The Royal College of Radiologists Clinical Oncology Information Network. Guidelines on the non-surgical management of lung cancer. Clin Oncol (R Coll Radiol) 1999; 11:S1-S53
328. Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 1992; 10:890-895
329. Irving JD, Dondelinger RF, Reidy JF, et al. Gianturco self-expanding stents: clinical experience in the vena cava and large veins. Cardiovasc Intervent Radiol 1992; 15:328-333
330. Hennequin LM, Fade O, Fays JG, et al. Superior vena cava stent placement: results with the Wallstent endoprosthesis. Radiology 1995; 196:353-361
331. Rosch J, Uchida BT, Hall LD, et al. Gianturco-Rosch expandable Z-stents in the treatment of superior vena cava syndrome. Cardiovasc Intervent Radiol 1992; 15:319-327
332. Bierdrager E, Lampmann LE, Lohle PN, et al. Endovascular stenting in neoplastic superior vena cava syndrome prior to chemotherapy or radiotherapy. Neth J Med 2005; 63:20-23
333. Chatziioannou A, Alexopoulos T, Mourikis D, et al. Stent therapy for malignant superior vena cava syndrome: should be first line therapy or simple adjunct to radiotherapy. Eur J Radiol 2003; 47:247-250
334. Courtheoux P, Alkofer B, Al Refai M, et al. Stent placement in superior vena cava syndrome. Ann Thorac Surg 2003; 75:158-161
335. de Gregorio Ariza MA, Gamboa P, Gimeno MJ, et al. Percutaneous treatment of superior vena cava syndrome using metallic stents. Eur Radiol 2003; 13:853-862
336. Garcia Monaco R, Bertoni H, Pallota G, et al. Use of self-expanding vascular endoprostheses in superior vena cava syndrome. Eur J Cardiothorac Surg 2003; 24:208-211
337. Greillier L, Barlesi F, Doddoli C, et al. Vascular stenting for palliation of superior vena cava obstruction in non-small-cell lung cancer patients: a future 'standard' procedure? Respiration 2004; 71:178-183
338. Kee ST, Kinoshita L, Razavi MK, et al. Superior vena cava syndrome: treatment with catheter-directed thrombolysis and endovascular stent placement. Radiology 1998; 206:187-193
339. Kim YI, Kim KS, Ko YC, et al. Endovascular stenting as a first choice for the palliation of superior vena cava syndrome. J Korean Med Sci 2004; 19:519-522
340. Lanciego C, Chacon JL, Julian A, et al. Stenting as first option for endovascular treatment of malignant superior vena cava syndrome. AJR Am J Roentgenol 2001; 177:585-593
341. Lau KY, Tan LT, Wong WW, et al. Brachiocephalic-superior vena cava metallic stenting in malignant superior vena cava obstruction. Ann Acad Med Singapore 2003; 32:461-465
342. Mathias K, Jager H, Willaschek J, et al. Interventional radiology in central venous obstructions: dilatation-stent implantation-thrombolysis. Radiologe 1998; 38:606-613
343. Nicholson AA, Ettles DF, Arnold A, et al. Treatment of malignant superior vena cava obstruction: metal stents or radiation therapy. J Vasc Interv Radiol 1997; 8:781-788
344. Tanigawa N, Sawada S, Mishima K, et al. Clinical outcome of stenting in superior vena cava syndrome associated with malignant tumors: comparison with conventional treatment. Acta Radiol 1998; 39:669-674
345. Urruticoechea A, Mesia R, Dominguez J, et al. Treatment of malignant superior vena cava syndrome by endovascular stent insertion: experience on 52 patients with lung cancer. Lung Cancer 2004; 43:209-214
346. Wilson E, Lyn E, Lynn A, et al. Radiological stenting provides effective palliation in malignant central venous obstruction. Clin Oncol (R Coll Radiol) 2002; 14:228-232
347. Colt HG, Meric B, Dumon JF. Double stents for carcinoma of the esophagus invading the tracheo-bronchial tree. Gastrointest Endosc 1992; 38:485-489
348. Freitag L, Tekolf E, Steveling H, et al. Management of malignant esophagotracheal fistulas with airway stenting and double stenting. Chest 1996; 110:1155-1160
349. Shin JH, Song HY, Ko GY, et al. Esophagorespiratory fistula: long-term results of palliative treatment with covered expandable metallic stents in 61 patients. Radiology 2004; 232:252-259
350. van den Bongard HJ, Boot H, Baas P, et al. The role of parallel stent insertion in patients with esophagorespiratory fistulas. Gastrointest Endosc 2002; 55:110-115
351. Yamamoto R, Tada H, Kishi A, et al. Double stent for malignant combined esophago-airway lesions. Jpn J Thorac Cardiovasc Surg 2002; 50:1-5
352. Hopwood P, Stephens RJ. Depression in patients with lung cancer: prevalence and risk factors derived from quality-of-life data. J Clin Oncol 2000; 18:893-903
353. Schwenk TL. Cancer and depression. Prim Care 1998; 25:505-513
354. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Seand 1983; 67:361-370
355. Boyar M, Raftopoulos H. Supportive care in lung cancer. Hematol Oncol Clin North Am 2005; 19:369-387
356. Patrick DL, Ferketich SL, Frame PS, et al. National Institutes of Health state-of-the-science conference statement; symptom management in cancer; pain, depression, and fatigue. J Natl Cancer Inst 2003; 95:1110-1117
357. Stone P, Richards M, A'Hern R, et al. A study to investigate the prevalence, severity and correlates of fatigue among patients with cancer in comparison with a control group of volunteers without cancer. Ann Oncol 2000; 11:561-567
358. Prakash UBS. Bronchoscopy. In: Mason RJ, Broaddus VC, Murray JF, et al, eds. Murray and Nadel's textbook of respiratory medicine: fourth edition. Philadelphia, PA: Elsevier Saunders, 2005; 1617-1650